NICE recommends Moventig (naloxegol) for treatment of opioid-induced constipation- AstraZeneca
The National Institute for Health and Care Excellence (NICE) in new final guidelines has recommended Moventig (naloxegol) from AstraZeneca as a cost-effective option for treating opioid-induced constipation in adults whose symptoms have not adequately responded to laxatives.
Comment: Moventig (Movantik in the US) is the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved in the European Union (EU). Opioids play an important role in chronic pain relief and work by binding to mu-receptors in the central nervous system, but they also bind to mu-receptors in the gastrointestinal tract, which can result in patients suffering from opioid-induced constipation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins